Mowery & Schoenfeld Wealth Management LLC Grows Position in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Mowery & Schoenfeld Wealth Management LLC lifted its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 750.0% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 68 shares of the company’s stock after purchasing an additional 60 shares during the quarter. Mowery & Schoenfeld Wealth Management LLC’s holdings in IDEXX Laboratories were worth $34,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. Riverview Trust Co acquired a new position in shares of IDEXX Laboratories in the first quarter worth about $26,000. OneAscent Wealth Management LLC acquired a new position in IDEXX Laboratories in the 1st quarter worth about $206,000. Vicus Capital purchased a new position in IDEXX Laboratories during the first quarter worth approximately $210,000. Aviance Capital Partners LLC acquired a new stake in IDEXX Laboratories in the first quarter valued at approximately $405,000. Finally, Oak Thistle LLC purchased a new stake in shares of IDEXX Laboratories in the first quarter valued at approximately $297,000. 87.84% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

IDXX has been the topic of a number of research analyst reports. JPMorgan Chase & Co. dropped their price target on shares of IDEXX Laboratories from $630.00 to $575.00 and set an “overweight” rating on the stock in a research note on Friday, October 11th. BTIG Research assumed coverage on shares of IDEXX Laboratories in a research note on Thursday, July 25th. They set a “buy” rating and a $580.00 target price for the company. StockNews.com lowered shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a research note on Wednesday, July 10th. Stifel Nicolaus cut their price objective on IDEXX Laboratories from $510.00 to $500.00 and set a “hold” rating for the company in a research note on Thursday, October 10th. Finally, Piper Sandler dropped their price target on IDEXX Laboratories from $600.00 to $520.00 and set a “neutral” rating for the company in a research report on Wednesday, August 14th. Three investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. Based on data from MarketBeat, IDEXX Laboratories presently has an average rating of “Moderate Buy” and a consensus price target of $574.13.

IDEXX Laboratories Trading Down 0.3 %

Shares of IDXX traded down $1.41 during mid-day trading on Thursday, reaching $456.49. The stock had a trading volume of 128,433 shares, compared to its average volume of 474,998. IDEXX Laboratories, Inc. has a 52-week low of $372.50 and a 52-week high of $583.39. The firm has a market cap of $37.70 billion, a price-to-earnings ratio of 44.39, a P/E/G ratio of 4.14 and a beta of 1.33. The business’s fifty day moving average is $486.11 and its 200 day moving average is $490.23. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.37 and a quick ratio of 1.03.

IDEXX Laboratories (NASDAQ:IDXX) last posted its quarterly earnings results on Tuesday, August 6th. The company reported $2.44 earnings per share for the quarter, missing the consensus estimate of $2.88 by ($0.44). IDEXX Laboratories had a net margin of 22.34% and a return on equity of 57.03%. The firm had revenue of $1 billion during the quarter, compared to analysts’ expectations of $1.01 billion. During the same period last year, the company earned $2.67 EPS. The business’s quarterly revenue was up 6.4% on a year-over-year basis. On average, sell-side analysts predict that IDEXX Laboratories, Inc. will post 10.44 EPS for the current fiscal year.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.